Skip to main content
Equibles

BARCLAYS PLC

Position in ZTS — Zoetis Inc.

CIK 312069 LONDON, X0
Back to ZTS Full portfolio

Position in ZTS

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$213,951,231
+$83,212,930 QoQ
Shares Held
1,809,925
+74.2% QoQ
Ownership
0.432%
of shares outstanding
% of Portfolio
0.09%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in ZTS Over Time

Shares Held

Position Value (USD)

Derivatives in ZTS

reported options exposure · as of Dec 31, 2025
CallValue
$4,089,150
CallShares
32,500
PutValue
$4,089,150
PutShares
32,500

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - Specialty & Generic

Healthcare · as of Mar 31, 2026

BARCLAYS PLC holds $516,666,064 across 52 Drug Manufacturers - Specialty & Generic names. ZTS ranks #1 (41.4% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ZTS
Zoetis Inc.
This page 		1,809,925 $213,951,231
2 INDV
Indivior Pharmaceuticals, Inc.
 1,745,751 $53,210,488
3 VTRS
Viatris Inc
 3,144,439 $42,481,369
4 TEVA
Teva Pharmaceutical Industries Ltd
 1,400,671 $42,188,210
5 UTHR
UNITED THERAPEUTICS Corp
 63,005 $37,360,703
6 NBIX
Neurocrine Biosciences Inc
 243,984 $32,142,450
7 AMLX
Amylyx Pharmaceuticals, Inc.
 971,854 $13,508,770
8 HIMS
Hims & Hers Health, Inc.
 639,372 $13,273,362

All Filings in ZTS

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $213,951,231 1,809,925
2025-12-31 $4,089,150 32,500
2025-12-31 $130,738,301 1,039,090
2025-12-31 $4,089,150 32,500
2025-09-30 $4,755,400 32,500
2025-09-30 $268,740,381 1,836,662
2025-09-30 $4,755,400 32,500
2025-06-30 $5,068,375 32,500
2025-06-30 $226,740,692 1,453,932
2025-06-30 $5,068,375 32,500
2025-03-31 $294,558,684 1,788,999
2024-12-31 $154,999,542 951,326
2024-12-31 $6,924,525 42,500
2024-12-31 $5,295,225 32,500
2024-09-30 $6,349,850 32,500
2024-09-30 $6,349,850 32,500
2024-09-30 $299,265,889 1,531,712
2024-06-30 $11,268,400 65,000
2024-06-30 $210,843,378 1,216,217
2024-03-31 $237,488,432 1,403,513
2023-12-31 $199,391,066 1,010,240
2023-09-30 $6,193,688 35,600
2023-09-30 $4,627,868 26,600
2023-09-30 $220,151,507 1,265,384
2023-06-30 $6,130,676 35,600
2023-06-30 $4,580,786 26,600
2023-06-30 $149,112,160 865,874
2023-03-31 $69,803,104 419,389
2022-12-31 $112,060,040 764,654
2022-09-30 $92,441,611 623,384
2022-06-30 $94,280,288 548,492
2022-03-31 $125,895,704 667,563
2022-03-31 $7,656,754 40,600
2021-12-31 $272,131,029 1,115,154
2021-09-30 $175,915,300 906,126
2021-06-30 $1,621,332 8,700
2021-06-30 $120,506,337 646,632
2021-03-31 $95,166,580 604,309
2020-12-31 $1,158,500 7,000
2020-12-31 $182,050 1,100
2020-12-31 $152,146,962 919,317
2020-09-30 $181,907 1,100
2020-09-30 $317,435,816 1,919,549
2020-09-30 $1,174,127 7,100
2020-06-30 $106,973,011 780,597
2020-06-30 $972,984 7,100
2020-06-30 $150,744 1,100
2020-03-31 $2,306,724 19,600
2020-03-31 $953,289 8,100
2020-03-31 $97,882,183 831,695

Report a Problem

Category
Description
Email (optional, for follow-up)